Ask a research question about Gaucher Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Gaucher Disease
creation_date: '2026-01-07T17:31:51Z'
updated_date: '2026-04-27T01:12:02Z'
category: Genetic
parents:
- Lysosomal Storage Disorder
- Sphingolipidosis
disease_term:
preferred_term: Gaucher disease
term:
id: MONDO:0018150
label: Gaucher disease
synonyms:
- Acid beta-glucosidase deficiency
- Glucocerebrosidase deficiency
definitions:
- name: Orphanet disease definition
definition_type: OTHER
description: >
Orphanet defines Gaucher disease as a lysosomal storage disorder spanning
three main forms plus fetal and cardiac-involvement variants.
scope: Orphanet structured disease record for ORPHA:355
evidence:
- reference: ORPHA:355
reference_title: "Gaucher disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Gaucher disease (GD) is a lysosomal storage disorder encompassing three main forms (types 1, 2 and 3), a fetal form and a variant with cardiac involvement (Gaucher disease - ophthalmoplegia - cardiovascular calcification or Gaucher-like disease)."
explanation: Orphanet defines Gaucher disease as a lysosomal storage disorder with the major clinical forms represented in this entry.
external_assertions:
- name: Orphanet Gaucher disease record
source: Orphanet
assertion_type: Disease registry record
external_id: ORPHA:355
url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=355
description: >
Orphanet ORPHA:355 is the structured registry record for Gaucher disease and
lists exact MONDO and other disease-code cross-references.
evidence:
- reference: ORPHA:355
reference_title: "Gaucher disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "MONDO:0018150 | Exact"
explanation: Orphanet maps ORPHA:355 exactly to the MONDO term used as the disease anchor in this file.
- reference: ORPHA:355
reference_title: "Gaucher disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "ICD-10:E75.2 | Narrower"
explanation: Orphanet lists ICD-10 E75.2 as a narrower cross-reference under the Gaucher disease record.
- reference: ORPHA:355
reference_title: "Gaucher disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "OMIM:230800 | Broader"
explanation: Orphanet lists OMIM 230800 as one of the broader OMIM cross-references for Gaucher disease.
has_subtypes:
- name: Type 1
display_name: Type 1 (Non-neuronopathic)
subtype_term:
preferred_term: Gaucher disease type I
term:
id: MONDO:0009265
label: Gaucher disease type I
subtype_frequency: "94%"
description: >
Most common form, accounting for ~94% of cases. No primary CNS
involvement. Characterized by hepatosplenomegaly, cytopenias, and
bone disease. Highly variable onset from childhood to adulthood.
Highest prevalence in Ashkenazi Jewish population.
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "Type-1 Gaucher disease, which affects the majority of patients (90% in Europe and USA, but less in other regions), is characterized by effects on the viscera"
explanation: Review confirms Type 1 is the most common form with visceral manifestations.
- name: Type 2
display_name: Type 2 (Acute neuronopathic)
subtype_term:
preferred_term: Gaucher disease type II
term:
id: MONDO:0009266
label: Gaucher disease type II
subtype_frequency: "1%"
description: >
Severe infantile-onset neuronopathic form. Presents before 6 months
with rapidly progressive neurodegeneration including bulbar signs,
oculomotor apraxia, opisthotonus, and seizures. Death typically
by age 2 years. ERT does not improve neurological outcomes.
evidence:
- reference: PMID:25755533
reference_title: "Gaucher disease."
supports: SUPPORT
snippet: "Type 2 is a more severe neuronopathic form leading to mortality by 2 years of age."
explanation: Review confirms Type 2 has severe neuronopathic course with early mortality.
- name: Type 3
display_name: Type 3 (Chronic neuronopathic)
subtype_term:
preferred_term: Gaucher disease type III
term:
id: MONDO:0009267
label: Gaucher disease type III
subtype_frequency: "5%"
description: >
Chronic neuronopathic form with both systemic and neurological involvement.
Onset in childhood with slower neurological progression than Type 2.
Hallmark feature is horizontal supranuclear gaze palsy. May also
develop myoclonic epilepsy and cognitive decline. Survival into adulthood.
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "types 2 and 3 are also associated with neurological impairment, either severe in type 2 or variable in type 3"
explanation: Review confirms Type 3 has variable neurological involvement distinct from severe Type 2.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_gba1_glucocerebroside_lysosomal_storage_model
hypothesis_label: Canonical GBA1 Glucocerebroside Lysosomal Storage Model
status: CANONICAL
description: >-
Biallelic GBA1 pathogenic variants reduce lysosomal glucocerebrosidase (GBA, acid β-glucosidase) activity, blocking the hydrolysis of glucosylceramide (glucocerebroside) to ceramide and glucose. Glucosylceramide and its derivatives accumulate within macrophage lysosomes, producing characteristic lipid-laden "Gaucher cells" in spleen, liver, bone marrow, and (in neuronopathic forms) the CNS. The pathological consequences span hepatosplenomegaly, cytopenias, skeletal disease (bone crises, osteonecrosis, osteopenia), and — for GBA1 variants of higher severity — progressive neuronopathy (Gaucher types 2 and 3) with brainstem and cerebellar dysfunction. Enzyme replacement therapy with recombinant glucocerebrosidase and substrate-reduction therapy with glucosylceramide synthase inhibitors both target this canonical chain.
notes: >-
Retained as CANONICAL. The 2026 openscientist
hypothesis-search report
(kb/hypotheses/Gaucher_Disease/canonical_gba1_glucocerebroside_lysosomal_storage_model)
confirms the GBA1 → GCase deficiency → GlcCer macrophage-lysosome
accumulation chain. Strongest validation: concordant clinical
efficacy of enzyme replacement therapy (ERT, exogenous GCase) and
substrate reduction therapy (SRT, GCS inhibitors) — two mechanistically
orthogonal approaches both reverse hematologic/visceral/biomarker
abnormalities in GD1. Five qualifications: (1) GlcSph (deacylated
glucosylsphingosine) may be the primary toxic species, not GlcCer
itself; (2) GBA1 heterozygosity is a major risk factor for
Parkinson's disease via α-synuclein clearance impairment;
(3) neuronopathic GD2/GD3 phenotype is BBB-limited and remains a
therapeutic gap; (4) skeletal disease responds incompletely to ERT;
(5) bone-marrow Gaucher-cell inflammation amplifies pathology beyond
storage alone.
evidence:
- reference: PMID:10464619
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "the presence of a single N370S allele is diagnostic of the type 1 or nonneuronopathic"
explanation: >
Canonical mechanism review used as the seed reference for the
hypothesis-search deep-research run.
pathophysiology:
- name: GBA1 Mutation
description: >
Biallelic GBA1 pathogenic variants reduce lysosomal glucocerebrosidase
activity through catalytic loss, protein misfolding, or impaired delivery
to the lysosome. Genotype severity helps shape the clinical path: at least
one N370S allele is associated with non-neuronopathic disease, while L444P
homozygosity is strongly associated with neuronopathic disease.
genes:
- preferred_term: GBA1
term:
id: hgnc:4177
label: GBA
downstream:
- target: Glucocerebrosidase Deficiency
description: GBA1 mutations reduce or abolish glucocerebrosidase enzyme activity.
causal_link_type: DIRECT
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Mutations in the GBA1 gene lead to a marked decrease in GCase activity."
explanation: This review directly links pathogenic GBA1 mutations to reduced glucocerebrosidase activity.
evidence:
- reference: PMID:10464619
reference_title: "Gaucher disease: gene frequencies and genotype/phenotype correlations."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "the presence of a single N370S allele is diagnostic of the type 1 or nonneuronopathic variant, whereas the L444P/L444P genotype is highly associated with neuronopathic variants in the Caucasian population."
explanation: This genotype-phenotype review supports the mutation severity branch used in the pathograph.
- name: Glucocerebrosidase Deficiency
conforms_to: "lysosomal_substrate_accumulation#Lysosomal Hydrolase or Cofactor Deficiency"
description: >
Deficient beta-glucocerebrosidase (glucosylceramidase) enzyme activity
resulting from GBA1 mutations.
genes:
- preferred_term: GBA1
term:
id: hgnc:4177
label: GBA
molecular_functions:
- preferred_term: glucocerebrosidase activity
term:
id: GO:0004348
label: glucosylceramidase activity
downstream:
- target: Impaired Sphingolipid Catabolism
description: Loss of glucocerebrosidase activity impairs lysosomal degradation of glucosylceramide.
causal_link_type: DIRECT
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "This leads to a markedly decreased activity of the lysosomal enzyme, glucocerebrosidase (GCase, also called glucosylceramidase or acid β-glucosidase, EC: 4.2.1.25), which hydrolyzes glucosylceramide (GlcCer) into ceramide and glucose"
explanation: The review describes the normal GCase reaction and therefore supports impaired glucosylceramide catabolism when the enzyme is deficient.
- target: Neuronal Glycosphingolipid Accumulation
description: Very low residual GCase activity in severe genotypes permits neuronal glycosphingolipid storage.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- low residual GCase activity in neuronopathic genotypes
- neuronal glucosylceramide and glucosylsphingosine accumulation
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "GlcCer turnover in neurons is low and its accumulation is only significant when residual GCase activity is drastically decreased, i.e., only with some types of GBA1 mutations"
explanation: This supports the severe-genotype branch from GCase deficiency to neuronal lipid accumulation.
- target: GBA1-Associated Alpha-Synuclein Proteostasis
description: Reduced GCase activity can impair autophagy and alpha-synuclein turnover, linking GBA1 mutations to Parkinson disease risk.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- reduced lysosomal GCase activity
- impaired autophagic turnover of alpha-synuclein
evidence:
- reference: PMID:30315684
reference_title: "Neurological effects of glucocerebrosidase gene mutations."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "A number of mechanisms have been proposed by which loss of function could lead to GD and PD. Predominantly, these are accumulation of enzyme substrate (GD and PD) and failure of autophagic pathways leading to reduced disposal of alpha synuclein"
explanation: This review supports the mechanistic link from GCase loss of function to impaired alpha-synuclein disposal.
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "It is caused by a deficiency of the lysosomal enzyme, glucocerebrosidase, which leads to an accumulation of its substrate, glucosylceramide, in macrophages."
explanation: Review confirms glucocerebrosidase deficiency causes glucosylceramide accumulation in macrophages.
- name: Impaired Sphingolipid Catabolism
description: >
Deficient glucocerebrosidase cannot degrade glucocerebroside (glucosylceramide) in lysosomes,
leading to substrate accumulation.
biological_processes:
- preferred_term: Sphingolipid Catabolism
term:
id: GO:0030149
label: sphingolipid catabolic process
modifier: DECREASED
downstream:
- target: Glucocerebroside Accumulation in Macrophages
description: Undegraded glucosylceramide accumulates primarily in macrophages.
causal_link_type: DIRECT
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "It is caused by a deficiency of the lysosomal enzyme, glucocerebrosidase, which leads to an accumulation of its substrate, glucosylceramide, in macrophages."
explanation: The review directly connects GCase deficiency with macrophage glucosylceramide accumulation.
- target: Glucosylsphingosine Accumulation
description: GCase deficiency favors alternative conversion of glucosylceramide to glucosylsphingosine.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- ceramidase-mediated deacylation of glucosylceramide
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "GlcCer is also the substrate of an alternative pathway in which a ceramidase transforms it into glucosylsphingosine"
explanation: This supports glucosylsphingosine as a downstream metabolite of accumulated glucosylceramide.
- name: Glucocerebroside Accumulation in Macrophages
conforms_to: "lysosomal_substrate_accumulation#Lysosomal Substrate Accumulation"
description: >
Glucocerebroside accumulates primarily in macrophages due to their role in
phagocytosis and membrane turnover.
cell_types:
- preferred_term: Macrophage
term:
id: CL:0000235
label: macrophage
downstream:
- target: Gaucher Cell Formation
description: Lipid-laden macrophages become Gaucher cells.
causal_link_type: DIRECT
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Mutations in the GBA1 gene lead to a marked decrease in GCase activity. The consequences of this deficiency are generally attributed to the accumulation of the GCase substrate, GlcCer, in macrophages, inducing their transformation into Gaucher cells."
explanation: This directly supports the transformation from lipid-loaded macrophages to Gaucher cells.
- name: Gaucher Cell Formation
description: >
Lipid-laden macrophages (Gaucher cells) accumulate in spleen, liver, bone marrow, and other organs.
These cells have characteristic crinkled tissue paper appearance and cause organ dysfunction
through infiltration and inflammatory cytokine release.
cell_types:
- preferred_term: Macrophage
term:
id: CL:0000235
label: macrophage
biological_processes:
- preferred_term: Macrophage Activation
term:
id: GO:0042116
label: macrophage activation
downstream:
- target: Visceral Reticuloendothelial Infiltration
description: Gaucher cells infiltrate spleen and liver, causing reticuloendothelial organ enlargement.
causal_link_type: DIRECT
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells."
explanation: This directly supports Gaucher cell infiltration of spleen and liver as the upstream mechanism for organomegaly.
- target: Bone Marrow Infiltration and Hematopoietic Suppression
description: Gaucher cell infiltration of marrow disrupts hematopoietic space and contributes to cytopenias.
causal_link_type: DIRECT
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells."
explanation: This directly supports marrow infiltration as a cause of cytopenias.
- target: Gaucher Skeletal Remodeling and Bone Infarction
description: Marrow Gaucher cells and lipid-driven vascular compression initiate skeletal involvement.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- marrow infiltration
- vascular compression
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "GlcCer accumulation in Gaucher cells is considered the first step towards bone involvement, leading to the vascular compression which is the source of necrotic complications"
explanation: This supports the skeletal branch from Gaucher cell storage to bone lesions and infarction.
- target: Macrophage Inflammatory Mediator Release
description: Gaucher and activated monocyte/macrophage populations release cytokines, chemokines, chitotriosidase, and CCL18.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Gaucher-cell polarization
- monocyte/macrophage activation
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Thus numerous cytokines, chemokines and other molecules—including IL-1β, IL-6, IL-8, TNFα (Tumor Necrosis Factor), M-CSF (Macrophage-Colony Stimulating Factor), MIP-1β, IL-18, IL-10, TGFβ, CCL-18, chitotriosidase, CD14s, and CD163s—are present in increased amounts in Gaucher patients’ plasma and could be implicated in hematological and bone complications"
explanation: This supports inflammatory mediator release downstream of macrophage involvement in Gaucher disease.
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells."
explanation: Review confirms Gaucher cell infiltration causes the major clinical manifestations.
- name: Visceral Reticuloendothelial Infiltration
description: >
Gaucher cells accumulate in reticuloendothelial organs, especially spleen
and liver, producing splenomegaly and hepatomegaly.
locations:
- preferred_term: spleen
term:
id: UBERON:0002106
label: spleen
- preferred_term: liver
term:
id: UBERON:0002107
label: liver
downstream:
- target: Hepatomegaly
description: Liver infiltration by Gaucher cells enlarges the liver.
causal_link_type: DIRECT
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells."
explanation: This directly links liver Gaucher cell infiltration to hepatomegaly.
- target: Splenomegaly
description: Spleen infiltration by Gaucher cells enlarges the spleen.
causal_link_type: DIRECT
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells."
explanation: This directly links spleen Gaucher cell infiltration to splenomegaly.
- name: Bone Marrow Infiltration and Hematopoietic Suppression
description: >
Bone marrow infiltration by Gaucher cells reduces effective hematopoietic
reserve and contributes to anemia and thrombocytopenia.
locations:
- preferred_term: bone marrow
term:
id: UBERON:0002371
label: bone marrow
biological_processes:
- preferred_term: hemopoiesis
modifier: DECREASED
term:
id: GO:0030097
label: hemopoiesis
downstream:
- target: Thrombocytopenia
description: Marrow infiltration and splenic involvement reduce circulating platelet counts.
causal_link_type: DIRECT
evidence:
- reference: PMID:19047232
reference_title: "Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "More than 50% of patients had platelet counts of <100000 platelets per mm3 at baseline, but >95% had platelet counts above this level after 8 years of treatment."
explanation: This cohort documents thrombocytopenia as a common downstream hematologic phenotype.
- target: Anemia
description: Marrow infiltration contributes to reduced red-cell output and anemia.
causal_link_type: DIRECT
evidence:
- reference: PMID:19047232
reference_title: "Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Anemia, although not severe, was present in >50% of patients at baseline and resolved for all patients after 8 years of treatment."
explanation: This cohort documents anemia as a common downstream hematologic phenotype.
- name: Macrophage Inflammatory Mediator Release
description: >
Gaucher disease includes activated monocyte/macrophage states and elevated
inflammatory mediators, with chitotriosidase and CCL18 reflecting Gaucher
cell burden and cytokines contributing to hematologic and skeletal disease.
cell_types:
- preferred_term: Macrophage
term:
id: CL:0000235
label: macrophage
biological_processes:
- preferred_term: inflammatory response
modifier: INCREASED
term:
id: GO:0006954
label: inflammatory response
- preferred_term: macrophage activation
term:
id: GO:0042116
label: macrophage activation
downstream:
- target: Chitotriosidase
description: Activated Gaucher macrophages release chitotriosidase as a disease-burden biomarker.
causal_link_type: DIRECT
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "This is the case for chitotriosidase and CCL18, which thus constitute quite specific disease biomarkers"
explanation: This supports chitotriosidase as a macrophage-derived downstream biomarker.
- target: Gaucher Skeletal Remodeling and Bone Infarction
description: Inflammatory mediators stimulate bone resorption and contribute to skeletal disease.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- osteoclast stimulation
- osteoblast inhibition
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Osteoporosis may be linked to IL-10, which inhibits osteoblast activity, but also to IL-1β, IL-6 and M-CSF, MIP-1α and MIP-1β, which stimulate bone resorption by increasing osteoclast activity"
explanation: This supports inflammatory mediator effects as part of the skeletal disease branch.
- name: Glucosylsphingosine Accumulation
description: >
GCase deficiency favors formation and accumulation of glucosylsphingosine
(Lyso-Gb1), a soluble bioactive sphingolipid that contributes to neuronopathic
toxicity and may also affect bone.
biological_processes:
- preferred_term: Sphingolipid Catabolism
term:
id: GO:0030149
label: sphingolipid catabolic process
modifier: DECREASED
downstream:
- target: Neuronal Glycosphingolipid Accumulation
description: Glucosylsphingosine accumulation in brain contributes to neuronal dysfunction and death.
causal_link_type: DIRECT
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "the accumulation of glucosylsphingosine may cause neuronal dysfunction and death, leading mainly to GD-related neurological symptoms"
explanation: This supports glucosylsphingosine accumulation as a proximal driver of neuronopathic disease.
- target: Gaucher Skeletal Remodeling and Bone Infarction
description: Sphingolipid imbalance, including sphingosine generated from glucosylsphingosine metabolism, contributes to skeletal toxicity.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- sphingosine generation
- bone-cell toxicity
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: PARTIAL
evidence_source: MODEL_ORGANISM
snippet: "Sphingosine could be particularly toxic to bone; in this model, deletion of GBA2 could reverse the Gaucher disease phenotype, particularly the bone abnormalities."
explanation: This mouse-model finding partially supports the sphingolipid branch contributing to bone disease.
- name: Gaucher Skeletal Remodeling and Bone Infarction
description: >
Gaucher cell infiltration, vascular compression, inflammatory cytokines, and
sphingolipid toxicity disrupt bone remodeling, lower bone mass, and promote
infarction or necrotic complications.
locations:
- preferred_term: bone marrow
term:
id: UBERON:0002371
label: bone marrow
biological_processes:
- preferred_term: bone remodeling
modifier: DYSREGULATED
term:
id: GO:0046849
label: bone remodeling
downstream:
- target: Bone Pain
description: Skeletal infiltration, bone crises, and infarction cause recurrent bone pain.
causal_link_type: DIRECT
evidence:
- reference: PMID:19047232
reference_title: "Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The parameters measured were hemoglobin levels, platelet counts, spleen and liver volumes, z scores for height and bone mineral density, and reports of bone pain and bone crises."
explanation: This cohort identifies bone pain and bone crises as measured skeletal manifestations in Gaucher disease.
- target: Pathologic Fractures
description: Low bone mass and disordered remodeling increase pathological fracture risk.
causal_link_type: DIRECT
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Loss of bone mass occurs earlier and is more severe in patients with GD and may cause pathological fractures (of long bones, vertebrae, etc.)."
explanation: This directly links bone mass loss to pathological fractures.
- target: Erlenmeyer Flask Deformity
description: Abnormal skeletal remodeling produces the characteristic distal femur deformity.
causal_link_type: DIRECT
evidence:
- reference: PMID:22010032
reference_title: "Quantifying the Erlenmeyer flask deformity."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Erlenmeyer flask deformity is a common radiological finding in patients with Gaucher's disease"
explanation: This supports Erlenmeyer flask deformity as a downstream skeletal phenotype.
- name: Neuronal Glycosphingolipid Accumulation
description: >
In neuronopathic forms (Types 2 and 3), severe glucocerebrosidase deficiency
leads to accumulation of glucosylceramide and glucosylsphingosine in neurons.
Glucosylsphingosine is normally absent from healthy brain but accumulates in
neuronopathic GD, causing direct neuronal toxicity and death.
subtypes:
- Type 2
- Type 3
cell_types:
- preferred_term: Neuron
term:
id: CL:0000540
label: neuron
locations:
- preferred_term: brain
term:
id: UBERON:0000955
label: brain
biological_processes:
- preferred_term: Neuron Apoptotic Process
term:
id: GO:0051402
label: neuron apoptotic process
downstream:
- target: Neuroinflammation
description: Neuronal lipid storage and injury are accompanied by microgliosis and astrogliosis.
causal_link_type: DIRECT
evidence:
- reference: PMID:30315684
reference_title: "Neurological effects of glucocerebrosidase gene mutations."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "A common feature appears to be microgliosis and subsequent astrogliosis and neuronal loss, particularly in hippocampal regions"
explanation: This supports glial activation downstream of neuronopathic substrate accumulation.
- target: Neurodegeneration and Bulbar-Pyramidal Dysfunction
description: Neuronal lipid toxicity causes neuronal dysfunction and death, producing oculomotor, bulbar, pyramidal, seizure, and developmental phenotypes.
causal_link_type: DIRECT
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "the accumulation of glucosylsphingosine may cause neuronal dysfunction and death, leading mainly to GD-related neurological symptoms"
explanation: This supports neuronal lipid toxicity as the upstream mechanism for neuronopathic clinical features.
evidence:
- reference: PMID:9497857
reference_title: "Gaucher's disease: clinical features and natural history."
supports: SUPPORT
snippet: "Severe deficiency of glucocerebrosidase caused by disabling mutations is additionally associated with neurological manifestations that in part reflect a failure to degrade endogenous neuronal glycosphingolipids"
explanation: Review explains that neuronopathic disease reflects failure to degrade neuronal glycosphingolipids.
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "the accumulation of glucosylsphingosine may cause neuronal dysfunction and death, leading mainly to GD-related neurological symptoms"
explanation: Review confirms glucosylsphingosine accumulation causes neuronal dysfunction and death.
- name: Neuroinflammation
description: >
Microglial activation and neuroinflammation contribute to neurodegeneration
in neuronopathic Gaucher disease.
subtypes:
- Type 2
- Type 3
cell_types:
- preferred_term: Microglial cell
term:
id: CL:0000129
label: microglial cell
biological_processes:
- preferred_term: Neuroinflammatory Response
term:
id: GO:0150076
label: neuroinflammatory response
downstream:
- target: Neurodegeneration and Bulbar-Pyramidal Dysfunction
description: Microgliosis and astrogliosis accompany neuronal loss and amplify neuronopathic disease.
causal_link_type: DIRECT
evidence:
- reference: PMID:30315684
reference_title: "Neurological effects of glucocerebrosidase gene mutations."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "A common feature appears to be microgliosis and subsequent astrogliosis and neuronal loss, particularly in hippocampal regions"
explanation: This supports inflammatory gliosis as a contributor to neuronal loss in neuronopathic Gaucher disease.
evidence:
- reference: PMID:30315684
reference_title: "Neurological effects of glucocerebrosidase gene mutations."
supports: SUPPORT
snippet: "A common feature appears to be microgliosis and subsequent astrogliosis and neuronal loss, particularly in hippocampal regions"
explanation: Review of postmortem and mouse model studies confirms microgliosis and astrogliosis as common neuropathological features in neuronopathic Gaucher disease.
- name: Neurodegeneration and Bulbar-Pyramidal Dysfunction
description: >
Neuronopathic Gaucher disease progresses through neuronal dysfunction and
loss in vulnerable CNS regions, producing supranuclear gaze palsy, bulbar
dysfunction, pyramidal or extrapyramidal signs, seizures, myoclonus, and
developmental impairment.
subtypes:
- Type 2
- Type 3
cell_types:
- preferred_term: Neuron
term:
id: CL:0000540
label: neuron
locations:
- preferred_term: brain
term:
id: UBERON:0000955
label: brain
downstream:
- target: Oculomotor Apraxia
description: Oculomotor pathway dysfunction causes impaired voluntary saccades in acute neuronopathic disease.
causal_link_type: DIRECT
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "oculomotor paralysis (or bilateral fixed strabismus) is very suggestive of the disease"
explanation: This supports oculomotor involvement as a downstream neuronopathic phenotype.
- target: Horizontal Supranuclear Gaze Palsy
description: Chronic neuronopathic disease commonly affects horizontal supranuclear gaze.
causal_link_type: DIRECT
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Some patients present moderate systemic involvement with horizontal ophthalmoplegia as the only neurological symptom"
explanation: This supports horizontal gaze palsy as a downstream Type 3 neurologic phenotype.
- target: Seizures
description: Progressive neuronal dysfunction produces seizures and myoclonic epilepsy.
causal_link_type: DIRECT
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Seizures occurring later manifest as myoclonic epilepsy that is resistant to antiepileptic drugs."
explanation: This supports seizures as a downstream neuronopathic phenotype.
- target: Myoclonus
description: Chronic neuronopathic disease may progress to myoclonus epilepsy.
causal_link_type: DIRECT
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "others present more severe forms with varying neurological signs including progressive myoclonus epilepsy (16% of patients)"
explanation: This supports myoclonus as a downstream Type 3 phenotype.
- target: Dysphagia
description: Bulbar dysfunction in acute neuronopathic disease causes swallowing impairment.
causal_link_type: DIRECT
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "bulbar signs (particularly severe swallowing disorders)"
explanation: This directly supports dysphagia as a downstream bulbar phenotype.
- target: Spasticity
description: Pyramidal tract involvement produces progressive spasticity and rigidity.
causal_link_type: DIRECT
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "hypertonia with pyramidal and possibly extrapyramidal rigidity"
explanation: This supports spasticity and rigidity as downstream pyramidal/extrapyramidal features.
- target: Global Developmental Delay
description: Early neuronopathic injury alters psychomotor development.
causal_link_type: DIRECT
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Psychomotor development is then altered, although some children may still continue to acquire skills."
explanation: This supports developmental delay as a downstream neuronopathic phenotype.
- target: Strabismus
description: Oculomotor pathway involvement may present as bilateral fixed strabismus.
causal_link_type: DIRECT
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "oculomotor paralysis (or bilateral fixed strabismus) is very suggestive of the disease"
explanation: This supports strabismus as a downstream oculomotor phenotype.
- target: Failure to Thrive
description: Severe neuronopathic and systemic disease in infancy contributes to growth failure and cachexia.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- bulbar dysfunction
- systemic disease burden
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "Growth retardation (30% of patients) may be the first sign, sometimes associated with cachexia."
explanation: This supports growth failure in severe Gaucher disease, while the causal link through neurologic and systemic disease remains indirect.
- name: GBA1-Associated Alpha-Synuclein Proteostasis
description: >
Reduced GCase activity and mutant GCase handling perturb autophagy and
alpha-synuclein turnover, creating a GBA1-linked Parkinson disease risk
branch that overlaps with but is distinct from classic neuronopathic Gaucher
disease.
cell_types:
- preferred_term: Neuron
term:
id: CL:0000540
label: neuron
locations:
- preferred_term: brain
term:
id: UBERON:0000955
label: brain
biological_processes:
- preferred_term: Sphingolipid Catabolism
term:
id: GO:0030149
label: sphingolipid catabolic process
modifier: DECREASED
downstream:
- target: Parkinsonism
description: Impaired alpha-synuclein proteostasis increases Parkinson disease risk and can manifest clinically as parkinsonism.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- alpha-synuclein accumulation
- Lewy pathology
- substantia nigra degeneration
evidence:
- reference: PMID:30315684
reference_title: "Neurological effects of glucocerebrosidase gene mutations."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Mutations of the GBA allele are the most significant genetic risk factor for idiopathic PD, found in 5%-20% of idiopathic PD cases depending on ethnicity."
explanation: This supports GBA1-linked Parkinson disease risk as a downstream phenotype branch.
evidence:
- reference: PMID:30315684
reference_title: "Neurological effects of glucocerebrosidase gene mutations."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In vitro studies have highlighted a bidirectional inverse correlation between GCase activity and alpha synuclein"
explanation: This supports a mechanistic relationship between GCase activity and alpha-synuclein proteostasis.
phenotypes:
- name: Hepatomegaly
category: Gastrointestinal
frequency: VERY_FREQUENT
diagnostic: true
notes: Often massive, may be first sign. Present across all subtypes.
phenotype_term:
preferred_term: Hepatomegaly
term:
id: HP:0002240
label: Hepatomegaly
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells."
explanation: Review confirms hepatomegaly as a major manifestation of Gaucher disease.
- reference: ORPHA:355
reference_title: "Gaucher disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002240 | Hepatomegaly | Very frequent (99-80%)"
explanation: Orphanet's curated HPO annotation independently classifies hepatomegaly as very frequent in Gaucher disease.
- name: Splenomegaly
category: Hematologic
frequency: VERY_FREQUENT
diagnostic: true
notes: Often massive, may require splenectomy
phenotype_term:
preferred_term: Splenomegaly
term:
id: HP:0001744
label: Splenomegaly
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells."
explanation: Review confirms splenomegaly as a major manifestation caused by Gaucher cell infiltration.
- reference: ORPHA:355
reference_title: "Gaucher disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001744 | Splenomegaly | Very frequent (99-80%)"
explanation: Orphanet's curated HPO annotation independently classifies splenomegaly as very frequent in Gaucher disease.
- name: Thrombocytopenia
category: Hematologic
frequency: FREQUENT
notes: Due to splenic sequestration and bone marrow infiltration
phenotype_term:
preferred_term: Thrombocytopenia
term:
id: HP:0001873
label: Thrombocytopenia
evidence:
- reference: PMID:19047232
reference_title: "Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1."
supports: SUPPORT
snippet: "More than 50% of patients had platelet counts of <100000 platelets per mm3 at baseline, but >95% had platelet counts above this level after 8 years of treatment."
explanation: Study documents thrombocytopenia as a common baseline finding in Gaucher disease patients.
- reference: ORPHA:355
reference_title: "Gaucher disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001873 | Thrombocytopenia | Frequent (79-30%)"
explanation: Orphanet's curated HPO annotation supports classifying thrombocytopenia as frequent in Gaucher disease.
- name: Anemia
category: Hematologic
frequency: VERY_FREQUENT
notes: Due to bone marrow infiltration
phenotype_term:
preferred_term: Anemia
term:
id: HP:0001903
label: Anemia
evidence:
- reference: PMID:19047232
reference_title: "Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1."
supports: SUPPORT
snippet: "Anemia, although not severe, was present in >50% of patients at baseline and resolved for all patients after 8 years of treatment."
explanation: Study confirms anemia as a common finding in over half of Gaucher disease patients.
- reference: ORPHA:355
reference_title: "Gaucher disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001903 | Anemia | Very frequent (99-80%)"
explanation: Orphanet's curated HPO annotation independently classifies anemia as very frequent in Gaucher disease.
- name: Fatigue
category: Constitutional
frequency: VERY_FREQUENT
notes: Orphanet classifies fatigue among the very frequent Gaucher disease phenotypes.
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
evidence:
- reference: ORPHA:355
reference_title: "Gaucher disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0012378 | Fatigue | Very frequent (99-80%)"
explanation: Orphanet's curated HPO annotation supports fatigue as a very frequent phenotype in Gaucher disease.
- name: Bone Pain
category: Musculoskeletal
frequency: FREQUENT
notes: Bone crises can be severe
phenotype_term:
preferred_term: Bone Pain
term:
id: HP:0002653
label: Bone pain
evidence:
- reference: PMID:19047232
reference_title: "Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1."
supports: SUPPORT
snippet: "Seventeen percent of patients reported a bone crisis before treatment and in the first 2 years of treatment, but no bone crises were reported after 2 years of enzyme replacement therapy."
explanation: Study documents bone crises/pain as a significant manifestation that resolves with treatment.
- reference: ORPHA:355
reference_title: "Gaucher disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002653 | Bone pain | Frequent (79-30%)"
explanation: Orphanet's curated HPO annotation supports classifying bone pain as frequent in Gaucher disease.
- name: Osteopenia
category: Musculoskeletal
frequency: FREQUENT
notes: Orphanet classifies osteopenia as a frequent skeletal phenotype.
phenotype_term:
preferred_term: Osteopenia
term:
id: HP:0000938
label: Osteopenia
evidence:
- reference: ORPHA:355
reference_title: "Gaucher disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000938 | Osteopenia | Frequent (79-30%)"
explanation: Orphanet's curated HPO annotation supports osteopenia as a frequent Gaucher disease phenotype.
- name: Pathologic Fractures
category: Musculoskeletal
frequency: FREQUENT
notes: Due to bone disease and osteopenia
phenotype_term:
preferred_term: Pathologic Fractures
term:
id: HP:0002756
label: Pathologic fracture
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "Loss of bone mass occurs earlier and is more severe in patients with GD and may cause pathological fractures (of long bones, vertebrae, etc.)."
explanation: Review confirms pathological fractures result from accelerated bone mass loss in Gaucher disease.
- name: Erlenmeyer Flask Deformity
category: Musculoskeletal
frequency: FREQUENT
notes: Characteristic bone remodeling defect in distal femur
phenotype_term:
preferred_term: Erlenmeyer Flask Deformity
term:
id: HP:0004975
label: Erlenmeyer flask deformity of the femurs
evidence:
- reference: PMID:22010032
reference_title: "Quantifying the Erlenmeyer flask deformity."
supports: SUPPORT
snippet: "Erlenmeyer flask deformity is a common radiological finding in patients with Gaucher's disease"
explanation: Study confirms Erlenmeyer flask deformity is a characteristic radiological finding in Gaucher disease.
- reference: ORPHA:355
reference_title: "Gaucher disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0004975 | Erlenmeyer flask deformity of the femurs | Frequent (79-30%)"
explanation: Orphanet's curated HPO annotation supports Erlenmeyer flask deformity as frequent in Gaucher disease.
# Neuronopathic phenotypes (Types 2 and 3)
- name: Oculomotor Apraxia
category: Neurologic
frequency: VERY_FREQUENT
subtype: Type 2
notes: Early sign in Type 2; in Type 3, presents as horizontal supranuclear gaze palsy
phenotype_term:
preferred_term: Oculomotor apraxia
term:
id: HP:0000657
label: Oculomotor apraxia
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "oculomotor paralysis (or bilateral fixed strabismus) is very suggestive of the disease"
explanation: Review identifies oculomotor paralysis as part of the diagnostic triad in Type 2.
- name: Horizontal Supranuclear Gaze Palsy
category: Neurologic
frequency: VERY_FREQUENT
subtype: Type 3
notes: Hallmark neurological feature of Type 3 Gaucher disease
phenotype_term:
preferred_term: Horizontal supranuclear gaze palsy
term:
id: HP:0007817
label: Horizontal supranuclear gaze palsy
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "Some patients present moderate systemic involvement with horizontal ophthalmoplegia as the only neurological symptom"
explanation: Review identifies horizontal ophthalmoplegia as the cardinal and sometimes sole neurological sign in Type 3.
- name: Seizures
category: Neurologic
frequency: VERY_FREQUENT
subtype: Type 2
notes: Severe seizures in Type 2; myoclonic epilepsy may occur in Type 3
phenotype_term:
preferred_term: Seizures
term:
id: HP:0001250
label: Seizure
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "Seizures occurring later manifest as myoclonic epilepsy that is resistant to antiepileptic drugs."
explanation: Review confirms seizures as a feature of Type 2, progressing to drug-resistant myoclonic epilepsy.
- name: Myoclonus
category: Neurologic
frequency: FREQUENT
subtype: Type 3
notes: Progressive myoclonic epilepsy is a feature of Type 3
phenotype_term:
preferred_term: Myoclonus
term:
id: HP:0001336
label: Myoclonus
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "others present more severe forms with varying neurological signs including progressive myoclonus epilepsy (16% of patients)"
explanation: Review documents progressive myoclonus epilepsy in 16% of Type 3 patients.
- name: Dysphagia
category: Neurologic
frequency: VERY_FREQUENT
subtype: Type 2
notes: Bulbar dysfunction with swallowing difficulty in Type 2
phenotype_term:
preferred_term: Dysphagia
term:
id: HP:0002015
label: Dysphagia
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "bulbar signs (particularly severe swallowing disorders)"
explanation: Review identifies severe swallowing disorders (dysphagia) as part of the Type 2 diagnostic triad.
- name: Spasticity
category: Neurologic
frequency: VERY_FREQUENT
subtype: Type 2
notes: Progressive spasticity and opisthotonus in Type 2
phenotype_term:
preferred_term: Progressive spasticity
term:
id: HP:0002191
label: Progressive spasticity
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "hypertonia with pyramidal and possibly extrapyramidal rigidity"
explanation: Review confirms pyramidal tract involvement with hypertonia and rigidity in Type 2.
- name: Global Developmental Delay
category: Neurologic
frequency: VERY_FREQUENT
subtype: Type 2
notes: Failure to achieve milestones in Type 2; developmental regression in Type 3
phenotype_term:
preferred_term: Global developmental delay
term:
id: HP:0001263
label: Global developmental delay
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "Psychomotor development is then altered, although some children may still continue to acquire skills."
explanation: Review confirms altered psychomotor development as a feature of Type 2.
- name: Strabismus
category: Neurologic
frequency: FREQUENT
subtype: Type 2
notes: Convergent strabismus may be present in neuronopathic forms
phenotype_term:
preferred_term: Strabismus
term:
id: HP:0000486
label: Strabismus
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "oculomotor paralysis (or bilateral fixed strabismus) is very suggestive of the disease"
explanation: Review identifies bilateral fixed strabismus as an alternative presentation of oculomotor involvement in Type 2.
- name: Failure to Thrive
category: Growth
frequency: VERY_FREQUENT
subtype: Type 2
phenotype_term:
preferred_term: Failure to thrive
term:
id: HP:0001508
label: Failure to thrive
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "Growth retardation (30% of patients) may be the first sign, sometimes associated with cachexia."
explanation: Review confirms growth retardation in 30% of Type 2 patients, sometimes with cachexia.
- name: Parkinsonism
category: Neurologic
subtype: Type 1
notes: >
GBA1 mutations increase Parkinson disease risk in Type 1 Gaucher disease
patients and carriers, although penetrance is incomplete.
phenotype_term:
preferred_term: Parkinsonism
term:
id: HP:0001300
label: Parkinsonism
evidence:
- reference: PMID:30315684
reference_title: "Neurological effects of glucocerebrosidase gene mutations."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Mutations of the GBA allele are the most significant genetic risk factor for idiopathic PD, found in 5%-20% of idiopathic PD cases depending on ethnicity."
explanation: This review supports GBA1 mutation-associated Parkinson disease risk.
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Patients with type-1 GD-but also carriers of GBA1 mutation-have been found to be predisposed to developing Parkinson's disease"
explanation: This Gaucher disease review specifically links Type 1 Gaucher disease and GBA1 carrier status to Parkinson disease predisposition.
biochemical:
- name: Beta-glucocerebrosidase Activity
presence: Decreased
context: Enzyme activity in leukocytes typically less than 15% of normal
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "A diagnosis of GD can be confirmed by demonstrating the deficiency of acid glucocerebrosidase activity in leukocytes."
explanation: Review confirms diagnosis via enzyme activity measurement in leukocytes.
- name: Chitotriosidase
presence: Elevated
context: Biomarker elevated in untreated Gaucher disease; reflects macrophage burden
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "This is the case for chitotriosidase and CCL18, which thus constitute quite specific disease biomarkers"
explanation: Review confirms chitotriosidase as a specific biomarker expressed by Gaucher cells.
- reference: PMID:25755533
reference_title: "Gaucher disease."
supports: SUPPORT
snippet: "Monitoring of patients on ERT involves evaluation of growth, blood counts, liver and spleen size and biomarkers such as chitotriosidase which reflect the disease burden."
explanation: Review confirms chitotriosidase is used for monitoring disease burden during ERT.
- name: Glucosylsphingosine (Lyso-Gb1)
presence: Elevated
context: Sensitive biomarker for diagnosis and monitoring; superior to chitotriosidase
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "Glucosylsphingosine is a novel biomarker whose sensitivity and specificity are superior to those of chitotriosidase and CCL18"
explanation: Review confirms glucosylsphingosine as superior biomarker to chitotriosidase for GD monitoring.
genetic:
- name: GBA1
gene_term:
preferred_term: GBA1
term:
id: hgnc:4177
label: GBA
association: Causative
subtype: Type 1
notes: >
Autosomal recessive. N370S is the most common mutation in Ashkenazi Jewish
population. The presence of at least one N370S allele is protective against
neuronopathic disease (diagnostic of Type 1).
variants:
- name: N370S homozygous
description: Most common genotype in Ashkenazi Jewish patients. Always non-neuronopathic (Type 1).
- name: N370S/other
description: Compound heterozygotes with N370S are Type 1.
evidence:
- reference: PMID:10464619
reference_title: "Gaucher disease: gene frequencies and genotype/phenotype correlations."
supports: SUPPORT
snippet: "the presence of a single N370S allele is diagnostic of the type 1 or nonneuronopathic variant"
explanation: Grabowski review confirms N370S allele is protective against neuronopathic disease.
- reference: CGGV:assertion_fbc5a876-f97e-4f9c-be99-664e2f6c8470-2020-06-24T160000.000Z
reference_title: "GBA1 / Gaucher disease (Definitive)"
supports: SUPPORT
evidence_source: OTHER
snippet: "GBA1 | HGNC:4177 | Gaucher disease | MONDO:0018150 | AR | Definitive"
explanation: ClinGen classifies the GBA1-Gaucher disease gene-disease relationship as definitive with autosomal recessive inheritance.
- name: GBA1
gene_term:
preferred_term: GBA1
term:
id: hgnc:4177
label: GBA
association: Causative
subtype: Type 2
notes: >
L444P homozygosity is strongly associated with neuronopathic variants.
Type 2 patients typically have severe mutations on both alleles with
minimal residual enzyme activity.
variants:
- name: L444P homozygous
description: Highly associated with neuronopathic variants in Caucasian population.
evidence:
- reference: PMID:10464619
reference_title: "Gaucher disease: gene frequencies and genotype/phenotype correlations."
supports: SUPPORT
snippet: "the L444P/L444P genotype is highly associated with neuronopathic variants in the Caucasian population"
explanation: Grabowski review confirms L444P homozygosity predicts neuronopathic disease.
- name: GBA1
gene_term:
preferred_term: GBA1
term:
id: hgnc:4177
label: GBA
association: Causative
subtype: Type 3
notes: >
Type 3 patients typically carry L444P or other severe mutations.
The D409H mutation is specifically associated with the cardiac
variant (Type 3c) with cardiovascular calcification.
variants:
- name: L444P homozygous
description: May present as Type 3 with slower neurological progression.
- name: D409H homozygous
description: Associated with cardiac variant with cardiovascular calcification.
- name: GBA1
gene_term:
preferred_term: GBA1
term:
id: hgnc:4177
label: GBA
association: Risk Factor
notes: >
GBA1 mutations (both homozygous and heterozygous) are the most
significant genetic risk factor for Parkinson disease. OR 5.43 across
centers. Found in 5-20% of idiopathic PD cases depending on ethnicity.
evidence:
- reference: PMID:19846850
reference_title: "Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease."
supports: SUPPORT
snippet: "The odds ratio for any GBA mutation in patients versus controls was 5.43 across centers."
explanation: Landmark multicenter NEJM study confirms strong GBA-Parkinson association with OR 5.43.
- reference: PMID:30315684
reference_title: "Neurological effects of glucocerebrosidase gene mutations."
supports: SUPPORT
snippet: "Mutations of the GBA allele are the most significant genetic risk factor for idiopathic PD, found in 5%-20% of idiopathic PD cases depending on ethnicity."
explanation: Review confirms GBA mutations are the most significant genetic risk factor for PD.
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "Patients with type-1 GD-but also carriers of GBA1 mutation-have been found to be predisposed to developing Parkinson's disease"
explanation: Review confirms both GD patients and GBA1 carriers have increased PD risk.
prevalence:
- population: Worldwide
percentage: "1-9 / 100 000"
notes: Orphanet reports worldwide prevalence at birth in the 1-9 per 100,000 class.
evidence:
- reference: ORPHA:355
reference_title: "Gaucher disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "1-9 / 100 000 | Worldwide | Prevalence at birth | PMID:23046562"
explanation: Orphanet provides a worldwide prevalence-at-birth class for Gaucher disease.
- population: Europe
percentage: "1-9 / 100 000"
notes: Orphanet reports both European annual incidence and point prevalence in the 1-9 per 100,000 class.
evidence:
- reference: ORPHA:355
reference_title: "Gaucher disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "1-9 / 100 000 | Europe | Point prevalence | EXPERT"
explanation: Orphanet provides a European point-prevalence class for Gaucher disease.
- subtype: Type 1
population: Global
notes: >
~94% of all Gaucher disease cases. Incidence ~1/40,000-1/60,000
in general population, ~1/800 in Ashkenazi Jews.
evidence:
- reference: PMID:28218669
reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
supports: SUPPORT
snippet: "In the general population, its incidence is approximately 1/40,000 to 1/60,000 births, rising to 1/800 in Ashkenazi Jews."
explanation: Review provides incidence estimates for Gaucher disease.
- subtype: Type 1
population: Ashkenazi Jewish
notes: Markedly increased prevalence due to founder effect; carrier frequency ~1/15.
evidence:
- reference: PMID:10464619
reference_title: "Gaucher disease: gene frequencies and genotype/phenotype correlations."
supports: SUPPORT
snippet: "Gaucher disease is the most prevalent lysosomal storage disease and has its highest incidence in the Ashkenazi Jewish population."
explanation: Review confirms highest incidence in Ashkenazi Jewish population.
progression:
- phase: Disease onset
age_range: All ages
notes: Orphanet records disease-level onset across all ages, complementing the subtype-specific onset patterns below.
evidence:
- reference: ORPHA:355
reference_title: "Gaucher disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Age of onset: All ages"
explanation: Orphanet's natural-history field supports broad all-age onset for Gaucher disease overall.
- phase: Onset
subtype: Type 1
age_range: Childhood-Adulthood
notes: Highly variable onset; some patients remain asymptomatic.
- phase: Onset
subtype: Type 2
age_range: 0-6 months
notes: Presents in first 6 months of life with rapid neurological deterioration.
evidence:
- reference: PMID:25755533
reference_title: "Gaucher disease."
supports: SUPPORT
snippet: "Type 2 is a more severe neuronopathic form leading to mortality by 2 years of age."
explanation: Review confirms early onset and rapid progression in Type 2.
- phase: Death
subtype: Type 2
age_range: by 2 years
notes: Death typically by age 2 years despite treatment.
- phase: Onset
subtype: Type 3
age_range: Childhood
notes: Neurological symptoms appear in childhood with slower progression than Type 2.
- phase: Chronic
subtype: Type 3
notes: Survival into adulthood with progressive neurological decline and systemic disease.
treatments:
- name: Enzyme Replacement Therapy
description: >
Imiglucerase, velaglucerase alfa, or taliglucerase alfa IV infusions
to replace deficient enzyme. Effective for visceral and hematologic
manifestations but does not cross the blood-brain barrier, so
neurological disease in Types 2 and 3 remains untreated.
treatment_term:
preferred_term: enzyme replacement therapy
term:
id: MAXO:0000933
label: enzyme replacement or supplementation therapy
target_mechanisms:
- target: Glucocerebrosidase Deficiency
treatment_effect: RESTORES
description: Recombinant enzyme replacement restores systemic glucocerebrosidase activity upstream of macrophage storage.
evidence:
- reference: PMID:19047232
reference_title: "Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Within 8 years of enzyme replacement therapy, most clinical parameters studied became normal or nearly normal."
explanation: Clinical response to enzyme replacement supports correction of the upstream systemic enzyme-deficiency pathway.
- target: Neuronal Glycosphingolipid Accumulation
treatment_effect: MODULATES
description: Intravenous enzyme replacement does not cross the blood-brain barrier sufficiently to treat neuronopathic disease.
evidence:
- reference: PMID:25755533
reference_title: "Gaucher disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "ERT is of no benefit in type 2 disease."
explanation: This supports lack of therapeutic effect on the neuronopathic branch.
evidence:
- reference: PMID:19047232
reference_title: "Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1."
supports: SUPPORT
snippet: "Within 8 years of enzyme replacement therapy, most clinical parameters studied became normal or nearly normal."
explanation: Long-term study demonstrates effectiveness of enzyme replacement therapy in children with Gaucher disease.
- reference: PMID:25755533
reference_title: "Gaucher disease."
supports: SUPPORT
snippet: "ERT is of no benefit in type 2 disease."
explanation: Review confirms ERT does not help neurological disease in Type 2 due to BBB.
- name: Substrate Reduction Therapy
description: >
Miglustat or eliglustat to reduce glucocerebroside synthesis.
Eliglustat is first-line oral therapy for Type 1. Miglustat
crosses the BBB but has not shown clear neurological benefit.
treatment_term:
preferred_term: substrate reduction therapy
term:
id: MAXO:0020025
label: substrate reduction therapy
target_mechanisms:
- target: Glucocerebroside Accumulation in Macrophages
treatment_effect: INHIBITS
description: Glucosylceramide synthase inhibition reduces substrate supply upstream of macrophage storage.
evidence:
- reference: PMID:25688781
reference_title: "Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "treatment with eliglustat compared with placebo for 9 months resulted in significant improvements in spleen volume, hemoglobin level, liver volume, and platelet count."
explanation: Clinical response to eliglustat supports substrate reduction acting upstream of visceral and hematologic manifestations.
evidence:
- reference: PMID:25688781
reference_title: "Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial."
supports: SUPPORT
snippet: "treatment with eliglustat compared with placebo for 9 months resulted in significant improvements in spleen volume, hemoglobin level, liver volume, and platelet count."
explanation: Phase 3 ENGAGE trial demonstrates eliglustat substrate reduction therapy effectively improves clinical manifestations in Gaucher disease.
- name: Supportive Care
description: Pain management, orthopedic interventions, transfusions as needed.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
- name: Genetic Counseling
description: Family screening, prenatal diagnosis available.
treatment_term:
preferred_term: genetic counseling
term:
id: MAXO:0000079
label: genetic counseling
inheritance:
- name: Autosomal recessive
inheritance_term:
preferred_term: Autosomal recessive
term:
id: HP:0000007
label: Autosomal recessive inheritance
evidence:
- reference: ORPHA:355
reference_title: "Gaucher disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Autosomal recessive"
explanation: Orphanet lists autosomal recessive inheritance for Gaucher disease.
datasets:
Gaucher disease (GD) is a lysosomal storage disorder caused by deficient activity of lysosomal acid β-glucosidase / glucocerebrosidase (GCase), leading to lysosomal accumulation of glucosylceramide (GlcCer) and its deacylated derivative glucosylsphingosine (GlcSph; lyso‑Gb1), particularly in macrophages, resulting in multi-organ disease (visceral, hematologic, skeletal; and sometimes neurologic) (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2, rossi2023noninvasivedbsbasedapproaches pages 1-2, dardis2022patientcenteredguidelines pages 1-2).
Clinical types (classical): - Type 1 (GD1): non-neuronopathic; accounts for ~90–95% of cases (cojbasicUnknownyeardiagnosisandmanagement pages 5-8, rossi2023noninvasivedbsbasedapproaches pages 1-2). - Type 2 (GD2): acute neuronopathic; rare, often fatal in early childhood (cojbasicUnknownyeardiagnosisandmanagement pages 5-8). - Type 3 (GD3): chronic neuronopathic; less common than GD1 (cojbasicUnknownyeardiagnosisandmanagement pages 5-8).
The information in this report is primarily derived from aggregated resources: international guideline synthesis (Dardis et al. 2022), narrative reviews (Giuffrida et al. 2023; Rossi et al. 2023), a population screening cohort (Chang et al. 2024), real-world registry analysis (GOS registry; Zimran et al. 2025), mechanistic animal-model work (Lin et al. 2024), and ClinicalTrials.gov trial records (chang2024newbornscreeningfor pages 1-2, dardis2022patientcenteredguidelines pages 8-9, zimran2025evaluationoflysogb1 pages 1-2, lin2024intrinsiclinkbetween pages 1-2, NCT05324943 chunk 1).
Primary cause: biallelic pathogenic variants in GBA1 encoding GCase (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2, dardis2022patientcenteredguidelines pages 1-2, dubiela2024longandshortterm pages 1-2).
Important alternative genetic etiology (Gaucher-like biochemistry/phenotype): If clinical/biochemical features are consistent with GD but no pathogenic GBA1 variants are found, international laboratory guidelines recommend considering saposin C deficiency and analyzing PSAP (prosaposin gene) (dardis2022patientcenteredguidelines pages 10-12).
No protective genetic or environmental factors were explicitly identified in the retrieved excerpts.
No explicit gene–environment interaction studies were identified in the retrieved excerpts. However, precision-genomics work argues that phenotypic heterogeneity may reflect multi-locus genetic contributions (saith2024concurrentgeneticdisorders pages 1-3, saith2025precisiongenomicprofiling pages 1-2).
From a recent clinical summary excerpt, common clinical findings include: - Splenomegaly: >90% (cojbasicUnknownyeardiagnosisandmanagement pages 5-8) - Hepatomegaly: 60–80% (cojbasicUnknownyeardiagnosisandmanagement pages 5-8) - Thrombocytopenia: ~90% (cojbasicUnknownyeardiagnosisandmanagement pages 5-8) - Anemia: 30–50% (cojbasicUnknownyeardiagnosisandmanagement pages 5-8) Skeletal involvement is common and may become irreversible if advanced (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2, cojbasicUnknownyeardiagnosisandmanagement pages 5-8).
Neurologic involvement distinguishes GD2 (acute severe) and GD3 (chronic neuronopathic) (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2, rossi2023noninvasivedbsbasedapproaches pages 1-2).
The retrieved excerpts do not provide standardized QoL instrument statistics (EQ‑5D/SF‑36). Bone disease and cytopenias plausibly drive morbidity, but such statements require additional QoL-specific sources.
Based on phenotypes explicitly discussed in retrieved sources: - Splenomegaly (HP:0001744) - Hepatomegaly (HP:0002240) - Thrombocytopenia (HP:0001873) - Anemia (HP:0001903) - Bone pain / skeletal dysplasia / osteonecrosis (multiple; skeletal involvement is explicit but granular HPO mapping would require additional phenotype-specific papers) (cojbasicUnknownyeardiagnosisandmanagement pages 5-8, giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2).
Mechanistic modifier evidence (animal model): - A 2024 mechanistic study reports that progranulin (PGRN; GRN) acts as a modifier of GCase biology and disease severity. In Grn−/− mice with graded Gba1 D409V dosages, higher mutant dosage produced earlier onset/shorter lifespan and more severe inflammation, lysosomal–autophagy dysfunction, gliosis, and α‑synuclein increases, supporting a threshold model for severity (lin2024intrinsiclinkbetween pages 1-2).
Human cohort precision-genomics evidence: - In a deeply phenotyped cohort with WES, ~6–6.5% of GD patients had additional genetic diagnoses contributing to “expanded/atypical” phenotypes, suggesting that some GD presentations behave as multi-locus disorders (saith2024concurrentgeneticdisorders pages 3-5, saith2024concurrentgeneticdisorders pages 1-3). - Example cohort statistics: among 275 patients, 18 (6.5%) had expanded phenotypes (preprint) (saith2024concurrentgeneticdisorders pages 3-5) and 17 (6.2%) had atypical phenotypes (peer-reviewed version) (saith2025precisiongenomicprofiling pages 1-2).
No epigenetic or chromosomal-abnormality evidence was identified in the retrieved excerpts.
No specific environmental, lifestyle, or infectious triggers were identified in the retrieved excerpts as causal contributors to GD. (GD is primarily genetic.)
Precision-genomic and mechanistic sources emphasize lipid-driven metabolic inflammation and lysosome-autophagy disruption: - “The accumulation of GlcCer and GlcSph in GD activates a range of pathways, including those involving inflammasomes, iron metabolism, necroptosis, ferroptosis, lysosomal function, autophagy, and reactive oxygen species (ROS).” (Saith et al. 2024 preprint excerpt) (saith2024concurrentgeneticdisorders pages 11-13). - PGRN/GRN modifier work demonstrates dose-dependent substrate accumulation, inflammatory responses, lysosomal–autophagy dysfunction, microgliosis, and α‑synuclein increases in mouse models (lin2024intrinsiclinkbetween pages 1-2).
Estimates vary across sources and populations: - General population incidence reported as ~1/40,000–1/60,000 (review) (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2) and GD1 incidence ~1/40,000–1/86,000 in non-Jewish populations (review) (rossi2023noninvasivedbsbasedapproaches pages 1-2). - In Ashkenazi Jews, incidence reported as ~1/450–1,000 live births (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2) and also ~1 in 850 in one registry-based review excerpt (zimran2025evaluationoflysogb1 pages 1-2). - Reported overall incidence range: 0.4–5.8 per 100,000 births and prevalence 0.7–1.8 per 100,000 (review) (rossi2023noninvasivedbsbasedapproaches pages 1-2).
A 2024 Shanghai cohort screened 50,108 newborns for 6 LSDs by MS/MS on DBS and confirmed 2 Gaucher diagnoses among 27 total LSD diagnoses; the combined 6-LSD birth prevalence was 1 in 1,856 live births, with 11.1% early-onset and 88.9% later-onset/subclinical forms among confirmed LSDs (chang2024newbornscreeningfor pages 1-2). This supports real-world feasibility of large-scale screening but Gaucher-specific precision is limited by the small number of Gaucher cases in this combined assay (chang2024newbornscreeningfor pages 1-2).
Core principle (guideline-level): GD diagnosis requires biochemical demonstration of deficient GCase/BGLU activity and confirmatory molecular testing where possible (dardis2022patientcenteredguidelines pages 1-2, dardis2022patientcenteredguidelines pages 8-9).
Gold-standard specimens: peripheral blood leukocytes and/or cultured skin fibroblasts (dardis2022patientcenteredguidelines pages 7-8, dardis2022patientcenteredguidelines pages 8-9).
DBS (dried blood spot): recommended as a first-line screen, but any low activity result must be confirmed in leukocytes/fibroblasts; DBS BGLU testing has low positive predictive value and should not be used alone for diagnosis (dardis2022patientcenteredguidelines pages 7-8, dardis2022patientcenteredguidelines pages 10-12).
Diagnostic enzyme-activity threshold: <15% of normal in leukocyte/fibroblast homogenates is diagnostic (dardis2022patientcenteredguidelines pages 7-8, dardis2022patientcenteredguidelines pages 8-9).
Abstract-supported quote (guideline): Dardis et al. emphasize that “Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder due to the deficient activity of the acid beta-glucosidase (GCase) enzyme, resulting in the progressive lysosomal accumulation of glucosylceramide (GlcCer) and its deacylated derivate, glucosylsphingosine (GlcSph).” (dardis2022patientcenteredguidelines pages 1-2).
Lyso‑Gb1 (GlcSph): - Widely characterized as a highly sensitive and specific biomarker for diagnosis and treatment monitoring (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2, zimran2025evaluationoflysogb1 pages 1-2). - Treatment decision support: a cohort study found a DBS lyso‑Gb1 cutoff >250 ng/mL was associated with initiation of GD-specific therapy (sensitivity 71%, specificity 87.5%), with treated patients showing higher median lyso‑Gb1 than untreated at diagnosis (dinur2023contributionofglucosylsphingosine pages 6-7). - Treatment monitoring dynamics: - Short-term: average 17% decrease 30 minutes after ERT infusion in 20 patients (dubiela2024longandshortterm pages 1-2). - Longitudinal: real-world registry analysis shows median change −8.6 ng/mL in treated vs +25.0 ng/mL untreated, and +19.5 ng/mL in those stopping treatment (zimran2025evaluationoflysogb1 pages 1-2).
Chitotriosidase: useful but lacks specificity and is confounded by common CHIT1 loss-of-function duplication; guideline notes interpretive complications (dardis2022patientcenteredguidelines pages 4-5, dubiela2024longandshortterm pages 1-2).
Guideline highlights: - GBA1 testing is complicated by a highly homologous pseudogene and recombinant alleles; some methods miss large deletions/recombinants; enzymatic confirmation is mandatory when variants of uncertain significance occur (dardis2022patientcenteredguidelines pages 8-9, dardis2022patientcenteredguidelines pages 9-10). - If GD phenotype/biochemistry but no GBA1 variants: consider PSAP/saposin C deficiency (dardis2022patientcenteredguidelines pages 10-12).
The retrieved excerpts do not provide modern, quantitative survival curves stratified by treatment era. They do note that ERT/SRT improved visceral/hematologic disease (especially GD1), while neuronopathic manifestations remain largely unresponsive to standard systemic therapies (kulkarni2024advancementsinviral pages 10-12, cojbasicUnknownyeardiagnosisandmanagement pages 5-8).
Enzyme replacement therapy (ERT): long-established cornerstone, generally effective for visceral and hematologic manifestations in GD1, but limited for neurologic disease (blood–brain barrier) (kulkarni2024advancementsinviral pages 10-12, giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2). - A review excerpt reports typical dosing 15–120 units/kg every 2 weeks, with most clinical/lab/radiologic improvements within ~6 months (except irreversible skeletal disease) (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2).
Substrate reduction therapy (SRT): improves visceral/hematologic manifestations and is used in adults with GD1; does not address CNS disease adequately (kulkarni2024advancementsinviral pages 10-12).
Lyso‑Gb1 is increasingly used to guide treatment decisions and monitor therapy response, including identifying when treatment may be indicated among mildly affected patients and detecting response after starting or stopping ERT (dinur2023contributionofglucosylsphingosine pages 6-7, zimran2025evaluationoflysogb1 pages 1-2).
Rationale: current ERT/SRT do not cross the blood–brain barrier and do not improve neuronopathic manifestations, motivating gene therapy strategies (kulkarni2024advancementsinviral pages 10-12).
Visual evidence note: Kulkarni et al. 2024 summarize multiple current clinical trials and identifiers in a dedicated section; the retrieved cropped images support these program listings (kulkarni2024advancementsinviral media cabb2850, kulkarni2024advancementsinviral media 3ff0cbdf).
Not applicable in the classic sense for a Mendelian recessive disorder, but reproductive and carrier-screening strategies are relevant.
Newborn screening: MS/MS-based screening with confirmatory biochemical/genetic testing can identify affected newborns, including later-onset forms; 2024 Shanghai data demonstrate implementation at scale (chang2024newbornscreeningfor pages 1-2).
The laboratory guideline emphasizes genetic testing as the most reliable method to identify carriers and recommends pre/post-test genetic counseling (dardis2022patientcenteredguidelines pages 8-9, dardis2022patientcenteredguidelines pages 9-10).
No naturally occurring veterinary Gaucher disease evidence was identified in the retrieved excerpts.
Mechanistic and therapeutic-development work relies heavily on mouse models of GD, including modifier models and neuronopathic models. A 2024 mechanistic study used genetically engineered mouse models combining PGRN deficiency with graded Gba1 D409V dosages to demonstrate threshold-like effects on severity, neuroinflammation, lysosome-autophagy dysfunction, and α‑synuclein accumulation (lin2024intrinsiclinkbetween pages 1-2).
| Topic | Key findings | Evidence type | Source (first author, year, journal or registry) | Publication date | URL | PMID | Notes |
|---|---|---|---|---|---|---|---|
| Diagnostics / genetics | International Working Group guideline: fluorometric leukocyte/fibroblast GCase assay is gold standard; DBS may be used first-line for screening but must be confirmed in leukocytes or fibroblasts; enzyme activity <15% of normal in leukocyte/fibroblast homogenates is diagnostic; >400 pathogenic GBA1 variants reported in abstract/background and 540 variants (403 GD-associated) noted in guideline text; GBA1 testing is complicated by a highly homologous pseudogene and recombinant alleles; ~10% of patients may carry large deletions/recombinant alleles; two diagnostic algorithms provided (dardis2022patientcenteredguidelines pages 8-9, dardis2022patientcenteredguidelines pages 9-10, dardis2022patientcenteredguidelines pages 1-2, dardis2022patientcenteredguidelines pages 7-8) | Guideline | Dardis, 2022, Orphanet Journal of Rare Diseases | Dec 2022 | https://doi.org/10.1186/s13023-022-02573-6 | not in retrieved text | Important limitation: DBS BGLU has poor positive predictive value and cannot stand alone for diagnosis; variants should be ACMG-classified; consider PSAP/saposin C deficiency if phenotype/biochemistry fit but GBA1 is negative (dardis2022patientcenteredguidelines pages 8-9, dardis2022patientcenteredguidelines pages 10-12) |
| Biomarkers / epidemiology / treatment | Lyso-Gb1 review: GD incidence estimated ~1/450–1,000 live births in Ashkenazi Jews, ~1/40,000–60,000 in general population; North-East Italy newborn-screening estimate 1/16,063; ERT typically 15–120 U/kg every 2 weeks; lyso-Gb1 described as the most promising biomarker with higher sensitivity/specificity than chitotriosidase (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2) | Review | Giuffrida, 2023, Orphanet Journal of Rare Diseases | Feb 2023 | https://doi.org/10.1186/s13023-023-02623-7 | not in retrieved text | Narrative review; stresses biomarker utility but exact cross-lab cutoffs vary (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2) |
| Biomarkers / treatment decision | Retrospective cohort of 97 newly diagnosed patients: 65 started GD-specific therapy; median lyso-Gb1 337 ng/mL in treated vs 153.5 ng/mL in untreated; proposed DBS cutoff >250 ng/mL associated with treatment initiation with 71% sensitivity and 87.5% specificity (dinur2023contributionofglucosylsphingosine pages 6-7) | Cohort study | Dinur, 2023, International Journal of Molecular Sciences | Feb 2023 | https://doi.org/10.3390/ijms24043945 | not in retrieved text | Authors caution that inter-laboratory methodology/units prevent direct universal adoption of this exact cutoff (dinur2023contributionofglucosylsphingosine pages 6-7) |
| Diagnostics / epidemiology / newborn screening | DBS-centered review/case-based report: incidence 0.4–5.8 per 100,000 births, prevalence 0.7–1.8 per 100,000; GD1 about 90% of cases; GD1 incidence in non-Jewish populations ~1/40,000–1/86,000, GD2 ~1/150,000, GD3 ~1/200,000; tissue glycolipids may rise 20–100×; illustrates first- and second-tier DBS workflow with low GCase and elevated lyso-Gb1 followed by molecular confirmation (rossi2023noninvasivedbsbasedapproaches pages 1-2) | Review / case-based diagnostic report | Rossi, 2023, Biomedicines | Sep 2023 | https://doi.org/10.3390/biomedicines11102672 | not in retrieved text | Useful for NBS-style workflows; not a population screening program outcome paper for GD alone (rossi2023noninvasivedbsbasedapproaches pages 1-2, rossi2023noninvasivedbsbasedapproaches pages 10-11) |
| Biomarkers / treatment monitoring | Eight-year ERT biomarker dynamics: GD1 coefficient of variation 34% vs GD3 23% (p=0.0003); in short-term testing, lyso-Gb1 fell by 17% within 30 min post-ERT (p<0.0001) in 20 patients; prior data summarized in paper show lyso-Gb1 can fall from median ~200 ng/mL pre-ERT to <50 ng/mL after ERT (dubiela2024longandshortterm pages 1-2) | Observational biomarker study | Dubiela, 2024, Biomolecules | Jul 2024 | https://doi.org/10.3390/biom14070842 | not in retrieved text | Highlights substantial intra-individual/inter-infusion variability; DBS timing relative to infusion matters (dubiela2024longandshortterm pages 1-2) |
| Newborn screening / epidemiology | Shanghai cohort of 50,108 newborns screened for 6 LSDs by MS/MS on DBS: 353 screened positive; 27 confirmed LSDs (1 in 1,856 live births overall), including 2 Gaucher cases; among all LSD diagnoses, 3/27 (11.1%) early-onset and 24/27 (88.9%) later-onset/subclinical forms (chang2024newbornscreeningfor pages 1-2) | Cohort newborn-screening study | Chang, 2024, JAMA Network Open | May 13, 2024 | https://doi.org/10.1001/jamanetworkopen.2024.10754 | not in retrieved text | Combined 6-LSD study, so Gaucher-specific prevalence estimate is based on only 2 cases; still highly relevant for real-world NBS implementation (chang2024newbornscreeningfor pages 1-2) |
| Biomarkers / registry / treatment outcomes | Gaucher Outcome Survey real-world study: of 2,007 registry participants, 435 met inclusion criteria; median lyso-Gb1 change from baseline to last assessment: −8.6 ng/mL in treated, +25.0 ng/mL untreated, +19.5 ng/mL after stopping treatment; treatment-naive had −120.5 ng/mL vs previously treated −3.3 ng/mL; velaglucerase alfa subgroup −32.6 ng/mL (zimran2025evaluationoflysogb1 pages 1-2) | Registry study | Zimran, 2025, Orphanet Journal of Rare Diseases | Jan 2025 | https://doi.org/10.1186/s13023-024-03444-y | not in retrieved text | Strong real-world support for lyso-Gb1 as a treatment-response biomarker using DBS; observational, not randomized (zimran2025evaluationoflysogb1 pages 1-2) |
| Gene therapy / GD1 | GALILEO-1 first-in-human study of FLT201: NCT05324943; Phase 1, open-label, single-group; 6 adults with GD1; single intravenous dose of a replication-incompetent ssAAV vector; primary outcome was treatment-emergent adverse events through Week 38; eligibility required stable ERT/SRT for at least 2 years and deficient GCase activity ≤30% of normal at diagnosis (NCT05324943 chunk 1, kulkarni2024advancementsinviral media cabb2850) | Clinical trial record | ClinicalTrials.gov / Spur Therapeutics, NCT05324943 | First posted Apr 13, 2022; completed Dec 4, 2024 | https://clinicaltrials.gov/study/NCT05324943 | not in retrieved text | Focused on safety/tolerability plus GCase augmentation; excludes splenectomy and anti-AAVS3 neutralizing antibodies (NCT05324943 chunk 1) |
| Gene therapy / GD1 confirmatory study | GALILEO-3 confirmatory FLT201 study: NCT07223944; Phase 3, non-randomized, single-group; estimated 45 adults with GD1 on stable ERT/SRT ≥2 years; single intravenous ssAAV FLT201 infusion; primary endpoint: proportion with stable hemoglobin (decrease no more than 1.5 g/dL) at Week 52 after discontinuing ERT/SRT (NCT07223944 chunk 1) | Clinical trial record | ClinicalTrials.gov / Spur Therapeutics, NCT07223944 | First posted Nov 3, 2025; recruiting as of Apr 21, 2026 | https://clinicaltrials.gov/study/NCT07223944 | not in retrieved text | Outside 2022–2025 publication window but highly relevant as latest implementation trajectory; MeSH term listed as Gaucher Disease D005776 in record (NCT07223944 chunk 1) |
| Gene therapy / GD peripheral disease | PROCEED: NCT05487599 of LY3884961 (PR001); Phase 1/2, multicenter, open-label, dose-finding; estimated 15 adults; single intravenous dose of replication-incompetent recombinant AAV; outcomes include AEs, spleen volume, platelet count, GCase, GlcSph, and time to discontinuation/re-initiation of ERT/SRT over 5 years (NCT05487599 chunk 1) | Clinical trial record | ClinicalTrials.gov / Prevail Therapeutics, NCT05487599 | First posted Aug 4, 2022; recruiting as of Apr 15, 2026 | https://clinicaltrials.gov/study/NCT05487599 | not in retrieved text | Requires centrally confirmed bi-allelic GBA1 variants and stable therapy; anti-AAV9 antibody titer must be ≤1:40 (NCT05487599 chunk 1) |
| Gene therapy / ex vivo HSC lentiviral | Guard1: NCT04145037 of AVR-RD-02; Phase 1/2, multinational open-label study; actual enrollment 8; intervention is autologous CD34+ HSCs genetically modified ex vivo with lentiviral vector encoding codon-optimized GCase, with busulfan conditioning; follow-up 52 weeks; sponsor states termination was voluntary and not based on safety or medical reasons (NCT04145037 chunk 1) | Clinical trial record | ClinicalTrials.gov / AVROBIO, NCT04145037 | First posted Oct 30, 2019; results posted Jan 18, 2024 | https://clinicaltrials.gov/study/NCT04145037 | not in retrieved text | Important proof-of-concept for cell-based gene therapy; small sample, early termination limits efficacy interpretation (NCT04145037 chunk 1) |
| Gene therapy / neuronopathic GD2 | VGN-R08b exploratory trial: NCT06272149; Early Phase 1, single-center, open-label, dose-climbing/expansion; estimated 6 infants ≤24 months with GD2; AAV9-human GBA1 delivered by intracerebroventricular injection; primary endpoint AEs/SAEs at Week 52; secondary endpoints include survival at 24 months, GCase activity, GC, and Lyso-GL1 in blood and CSF, plus immunogenicity (NCT06272149 chunk 1) | Clinical trial record | ClinicalTrials.gov / Xinhua Hospital, NCT06272149 | First posted Feb 22, 2024 | https://clinicaltrials.gov/study/NCT06272149 | not in retrieved text | Especially relevant for CNS-targeted therapy where ERT/SRT have limited neurologic benefit; excludes anti-AAV9 neutralizing antibody titer >1:5 (NCT06272149 chunk 1) |
Table: This table compiles recent high-yield evidence items for Gaucher disease across diagnostics, biomarkers, epidemiology, newborn screening, and emerging gene therapy. It is structured for direct use in a disease knowledge base and emphasizes quantitative thresholds, trial metadata, and implementation caveats.
References
(carubbi2026glucosylsphingosine(lysogb1)an pages 1-2): Francesca Carubbi, Silvia Linari, and Marco Spada. Glucosylsphingosine (lyso-gb1): an update on its use as a biomarker in gaucher disease. International Journal of Molecular Sciences, 27:1705, Feb 2026. URL: https://doi.org/10.3390/ijms27041705, doi:10.3390/ijms27041705. This article has 2 citations.
(giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2): Gaetano Giuffrida, Uros Markovic, Annalisa Condorelli, Valeria Calafiore, Daniela Nicolosi, Marianna Calagna, Stephanie Grasso, Marco Tindaro Valentino Ragusa, Jennifer Gentile, and Mariasanta Napolitano. Glucosylsphingosine (lyso-gb1) as a reliable biomarker in gaucher disease: a narrative review. Orphanet Journal of Rare Diseases, Feb 2023. URL: https://doi.org/10.1186/s13023-023-02623-7, doi:10.1186/s13023-023-02623-7. This article has 58 citations and is from a peer-reviewed journal.
(rossi2023noninvasivedbsbasedapproaches pages 1-2): Claudia Rossi, Rossella Ferrante, Silvia Valentinuzzi, Mirco Zucchelli, Carlotta Buccolini, Sara Di Rado, Daniela Trotta, Liborio Stuppia, Luca Federici, and Maurizio Aricò. Noninvasive dbs-based approaches to assist clinical diagnosis and treatment monitoring of gaucher disease. Biomedicines, 11:2672, Sep 2023. URL: https://doi.org/10.3390/biomedicines11102672, doi:10.3390/biomedicines11102672. This article has 12 citations.
(dardis2022patientcenteredguidelines pages 1-2): A. Dardis, H. Michelakakis, P. Rozenfeld, K. Fumic, J. Wagner, E. Pavan, M. Fuller, S. Revel-Vilk, D. Hughes, T. Cox, J. Aerts, and the International Working Group of Gaucher Disease. Patient centered guidelines for the laboratory diagnosis of gaucher disease type 1. Orphanet Journal of Rare Diseases, Dec 2022. URL: https://doi.org/10.1186/s13023-022-02573-6, doi:10.1186/s13023-022-02573-6. This article has 70 citations and is from a peer-reviewed journal.
(cojbasicUnknownyeardiagnosisandmanagement pages 5-8): I Ćojbašić. Diagnosis and management of gaucher disease: current approaches and emerging. Unknown journal, Unknown year.
(NCT07223944 chunk 1): A Gaucher Disease Gene Therapy Trial With FLT201. Spur Therapeutics. 2026. ClinicalTrials.gov Identifier: NCT07223944
(NCT05324943 chunk 1): A Gene Therapy Study in Patients With Gaucher Disease Type 1. Spur Therapeutics. 2022. ClinicalTrials.gov Identifier: NCT05324943
(chang2024newbornscreeningfor pages 1-2): Siyu Chang, Xia Zhan, Yuchao Liu, Huanlei Song, Zizhen Gong, Lianshu Han, Gustavo H. B. Maegawa, Xuefan Gu, and Huiwen Zhang. Newborn screening for 6 lysosomal storage disorders in china. JAMA Network Open, 7:e2410754, May 2024. URL: https://doi.org/10.1001/jamanetworkopen.2024.10754, doi:10.1001/jamanetworkopen.2024.10754. This article has 21 citations and is from a peer-reviewed journal.
(dardis2022patientcenteredguidelines pages 8-9): A. Dardis, H. Michelakakis, P. Rozenfeld, K. Fumic, J. Wagner, E. Pavan, M. Fuller, S. Revel-Vilk, D. Hughes, T. Cox, J. Aerts, and the International Working Group of Gaucher Disease. Patient centered guidelines for the laboratory diagnosis of gaucher disease type 1. Orphanet Journal of Rare Diseases, Dec 2022. URL: https://doi.org/10.1186/s13023-022-02573-6, doi:10.1186/s13023-022-02573-6. This article has 70 citations and is from a peer-reviewed journal.
(zimran2025evaluationoflysogb1 pages 1-2): Ari Zimran, Shoshana Revel-Vilk, Tama Dinur, Majdolen Istaiti, Jaco Botha, Elena Lukina, Pilar Giraldo, Patrick Deegan, and Stephan vom Dahl. Evaluation of lyso-gb1 as a biomarker for gaucher disease treatment outcomes using data from the gaucher outcome survey. Orphanet Journal of Rare Diseases, Jan 2025. URL: https://doi.org/10.1186/s13023-024-03444-y, doi:10.1186/s13023-024-03444-y. This article has 9 citations and is from a peer-reviewed journal.
(lin2024intrinsiclinkbetween pages 1-2): Yi Lin, Xiangli Zhao, Benjamin Liou, Venette Fannin, Wujuan Zhang, Kenneth D R Setchell, Xiaohong Wang, Dao Pan, Gregory A Grabowski, Chuan-ju Liu, and Ying Sun. Intrinsic link between pgrn and gba1 d409v mutation dosage in potentiating gaucher disease. Human molecular genetics, 33:1771-1788, Aug 2024. URL: https://doi.org/10.1093/hmg/ddae113, doi:10.1093/hmg/ddae113. This article has 6 citations and is from a domain leading peer-reviewed journal.
(dubiela2024longandshortterm pages 1-2): Pawel Dubiela, Paulina Szymanska-Rozek, Piotr Hasinski, Patryk Lipinski, Grazina Kleinotiene, Dorota Giersz, and Anna Tylki-Szymanska. Long- and short-term glucosphingosine (lyso-gb1) dynamics in gaucher patients undergoing enzyme replacement therapy. Biomolecules, 14:842, Jul 2024. URL: https://doi.org/10.3390/biom14070842, doi:10.3390/biom14070842. This article has 5 citations.
(dardis2022patientcenteredguidelines pages 10-12): A. Dardis, H. Michelakakis, P. Rozenfeld, K. Fumic, J. Wagner, E. Pavan, M. Fuller, S. Revel-Vilk, D. Hughes, T. Cox, J. Aerts, and the International Working Group of Gaucher Disease. Patient centered guidelines for the laboratory diagnosis of gaucher disease type 1. Orphanet Journal of Rare Diseases, Dec 2022. URL: https://doi.org/10.1186/s13023-022-02573-6, doi:10.1186/s13023-022-02573-6. This article has 70 citations and is from a peer-reviewed journal.
(dardis2022patientcenteredguidelines pages 9-10): A. Dardis, H. Michelakakis, P. Rozenfeld, K. Fumic, J. Wagner, E. Pavan, M. Fuller, S. Revel-Vilk, D. Hughes, T. Cox, J. Aerts, and the International Working Group of Gaucher Disease. Patient centered guidelines for the laboratory diagnosis of gaucher disease type 1. Orphanet Journal of Rare Diseases, Dec 2022. URL: https://doi.org/10.1186/s13023-022-02573-6, doi:10.1186/s13023-022-02573-6. This article has 70 citations and is from a peer-reviewed journal.
(saith2024concurrentgeneticdisorders pages 1-3): Armaan Saith, Jiapeng Ruan, Noor Ul Ain, Maniya Kasaiyan, Dhanpat Jain, Gary Israel, Sameet Mehta, Nigel S. Bamford, Shiny Nair, and Pramod K. Mistry. Concurrent genetic disorders in gaucher disease: insights into complex phenotypes, genetic modifiers, and targeted therapies. Unknown journal, Dec 2024. URL: https://doi.org/10.20944/preprints202412.1836.v1, doi:10.20944/preprints202412.1836.v1.
(saith2025precisiongenomicprofiling pages 1-2): Armaan Saith, Noor Ul Ain, Jiapeng Ruan, Maniya Kasaiyan, Dhanpat Jain, Gary Israel, Sameet Mehta, Nigel S. Bamford, Shiny Nair, and Pramod K. Mistry. Precision genomic profiling in gaucher disease: insights from atypical presentations. Frontiers in Genetics, Nov 2025. URL: https://doi.org/10.3389/fgene.2025.1553036, doi:10.3389/fgene.2025.1553036. This article has 0 citations and is from a peer-reviewed journal.
(kulkarni2024advancementsinviral pages 10-12): Akhil Kulkarni, Tiffany Chen, Ellen Sidransky, and Tae-Un Han. Advancements in viral gene therapy for gaucher disease. Genes, 15:364, Mar 2024. URL: https://doi.org/10.3390/genes15030364, doi:10.3390/genes15030364. This article has 16 citations.
(saith2024concurrentgeneticdisorders pages 3-5): Armaan Saith, Jiapeng Ruan, Noor Ul Ain, Maniya Kasaiyan, Dhanpat Jain, Gary Israel, Sameet Mehta, Nigel S. Bamford, Shiny Nair, and Pramod K. Mistry. Concurrent genetic disorders in gaucher disease: insights into complex phenotypes, genetic modifiers, and targeted therapies. Unknown journal, Dec 2024. URL: https://doi.org/10.20944/preprints202412.1836.v1, doi:10.20944/preprints202412.1836.v1.
(saith2024concurrentgeneticdisorders pages 11-13): Armaan Saith, Jiapeng Ruan, Noor Ul Ain, Maniya Kasaiyan, Dhanpat Jain, Gary Israel, Sameet Mehta, Nigel S. Bamford, Shiny Nair, and Pramod K. Mistry. Concurrent genetic disorders in gaucher disease: insights into complex phenotypes, genetic modifiers, and targeted therapies. Unknown journal, Dec 2024. URL: https://doi.org/10.20944/preprints202412.1836.v1, doi:10.20944/preprints202412.1836.v1.
(NCT06272149 chunk 1): An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease. Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. 2023. ClinicalTrials.gov Identifier: NCT06272149
(dardis2022patientcenteredguidelines pages 7-8): A. Dardis, H. Michelakakis, P. Rozenfeld, K. Fumic, J. Wagner, E. Pavan, M. Fuller, S. Revel-Vilk, D. Hughes, T. Cox, J. Aerts, and the International Working Group of Gaucher Disease. Patient centered guidelines for the laboratory diagnosis of gaucher disease type 1. Orphanet Journal of Rare Diseases, Dec 2022. URL: https://doi.org/10.1186/s13023-022-02573-6, doi:10.1186/s13023-022-02573-6. This article has 70 citations and is from a peer-reviewed journal.
(dinur2023contributionofglucosylsphingosine pages 6-7): Tama Dinur, Peter Bauer, Christian Beetz, Claudia Cozma, Michal Becker-Cohen, Majdolen Istaiti, Arndt Rolfs, Volha Skrahina, Ari Zimran, and Shoshana Revel-Vilk. Contribution of glucosylsphingosine (lyso-gb1) to treatment decisions in patients with gaucher disease. International Journal of Molecular Sciences, 24:3945, Feb 2023. URL: https://doi.org/10.3390/ijms24043945, doi:10.3390/ijms24043945. This article has 16 citations.
(dardis2022patientcenteredguidelines pages 4-5): A. Dardis, H. Michelakakis, P. Rozenfeld, K. Fumic, J. Wagner, E. Pavan, M. Fuller, S. Revel-Vilk, D. Hughes, T. Cox, J. Aerts, and the International Working Group of Gaucher Disease. Patient centered guidelines for the laboratory diagnosis of gaucher disease type 1. Orphanet Journal of Rare Diseases, Dec 2022. URL: https://doi.org/10.1186/s13023-022-02573-6, doi:10.1186/s13023-022-02573-6. This article has 70 citations and is from a peer-reviewed journal.
(NCT05487599 chunk 1): A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED). Prevail Therapeutics. 2022. ClinicalTrials.gov Identifier: NCT05487599
(NCT04145037 chunk 1): Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease. AVROBIO. 2019. ClinicalTrials.gov Identifier: NCT04145037
(kulkarni2024advancementsinviral media cabb2850): Akhil Kulkarni, Tiffany Chen, Ellen Sidransky, and Tae-Un Han. Advancements in viral gene therapy for gaucher disease. Genes, 15:364, Mar 2024. URL: https://doi.org/10.3390/genes15030364, doi:10.3390/genes15030364. This article has 16 citations.
(kulkarni2024advancementsinviral media 3ff0cbdf): Akhil Kulkarni, Tiffany Chen, Ellen Sidransky, and Tae-Un Han. Advancements in viral gene therapy for gaucher disease. Genes, 15:364, Mar 2024. URL: https://doi.org/10.3390/genes15030364, doi:10.3390/genes15030364. This article has 16 citations.
(rossi2023noninvasivedbsbasedapproaches pages 10-11): Claudia Rossi, Rossella Ferrante, Silvia Valentinuzzi, Mirco Zucchelli, Carlotta Buccolini, Sara Di Rado, Daniela Trotta, Liborio Stuppia, Luca Federici, and Maurizio Aricò. Noninvasive dbs-based approaches to assist clinical diagnosis and treatment monitoring of gaucher disease. Biomedicines, 11:2672, Sep 2023. URL: https://doi.org/10.3390/biomedicines11102672, doi:10.3390/biomedicines11102672. This article has 12 citations.